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Objective: Studies have confirmed the safety of oropharyngeal administration of 
colostrum (OAC) in very low birth weight (VLBW) infants. However, the effect of 
OAC on immune system is inconclusive. This study aims to evaluate the effect of 
OAC on secretory Immunoglobulin A (sIgA) and lactoferrin in very low birth weight 
infants. 
Design: Randomized Controlled Trial. 
Setting: 40-bedded Neonatal Intensive Care Unit in a university children’s hospital in 
the People’s Republic of China. 
Patients: VLBW infants were allocated to the study group (n = 32) and control group 
(n = 32). 
Intervention: The intervention was oropharyngeal administration of 0.2 ml of their 
mother’s colostrum every 4 hours during 7 days. The control group received saline 
solution.  
Measurements and Main Results: sIgA and lactoferrin in urine and saliva were 
measured within 24 hours of life (baseline), at 7 and 21 days. Primary outcomes were 
changes of sIgA and lactoferrin in urine and saliva between baseline, at 7 and 21 days. 
Infant’s clinical data were also collected during hospitalization. 
Change from baseline in lactoferrin in saliva at 7 days (5.18±7.07 vs. -1.74±4.67 
µg/ml, p<0.001) and 21 days (5.31±9.74vs -1.17±10.38 µg/ml, p=0.02) shows 
statistic difference. No differences were found of lactoferrin in urine and also no 
differences of sIgA in urine and saliva. There were also no differences between days 




Conclusions: OAC can increases the level of lactoferrin in saliva in VLBW infants. 
No effect could be documented of sIgA and lactoferrin in urine. Larger trials are 






Colostrum is the first milk produced by the mammary when the tight junctions in the 
mammary epithelium are open (1).
 
It is rich in cytokines (anti-inflammatory cytokines, 
pro-inflammatory cytokines) and other immune agents such as secretory 
Immunoglobulin A (sIgA) and lactoferrin (2-7).
 
These immune agents can provide 
bacteriostatic, bactericidal, antiviral, anti-inflammatory and immunomodulatory 
protection against infection (8).
 
The tight junctions in the mammary epithelium 
usually closed after the first day of postnatal for women who give birth at term, much 
earlier than women who deliver preterm infants [9](9). As a result the immune 
protective factors are more highly concentrated in the colostrum of mothers delivering 
premature infants.
 
Studies confirmed that colostrum contains higher concentrations of 
immune-protective agents compared with mature human milk, such as lactoferrin, 
lysozyme, and sIgA (9-11). Therefore, giving colostrum as soon as excreted from 
their mother can provide more immunological support for immature preterm 
newborns. However, some VLBW infants can’t start enteral feeding because of 
clinical instability. For these infants, oropharyngeal exposure to protective biofactors 
from colostrum is delayed. Oropharyngeal administration of colostrum can be given 
to these infants to eliminate the delay. 
 Oropharyngeal Administration of Colostrum (OAC) is an intervention placing 
small amount of colostrum directly onto the oropharyngeal mucosa with a sterile 
syringe for absorption. In theory, OAC can promote immune response in three ways. 
First, colostrum is rich in cytokines, which can interact with cells within the 
oropharyngeal-associated lymphoid tissue (12). For example, Interleukin-6 can 
stimulate the growth and differentiation of B-lymphocytes to IgA-secreting plasma 
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cells and secreting sIgA can enhance local mucosal immunity (13). Secondly, 
colostrum has a high concentration of sIgA and lactoferrin. These factors can be 
absorbed by mucosal directly and interfere with bacterial colonization (14). Thirdly, 
during OAC some colostrum can travel to the gastrointestinal tract and interact with 
gut-associated lymphoid tissues (15). 
 Although theoretical support for the OAC exists, limited clinical evidence 
exists to prove the effects of oropharyngeal colostrum administration. Therefore, this 
study aims to evaluate the effect of OAC on sIgA and lactoferrin in VLBW infants. 
 
MATERIALS AND METHODS 
Study Design  
A double blind randomized controlled clinical trial was conducted from March 2015 
to October 2015 in the Neonatal Intensive Care Unit (NICU) of the stand-alone 
Children Hospital of Fudan University in Shanghai, China. 
Participants  
Inclusion criteria were infants with birth weight ≤1500g, transferred to our hospital 
within 24 hours after birth and parents agree to provide colostrum. Exclusion criteria 
were infants suffering from life-threatening conditions, such as severe heart disease, 
whose life time is expected less than 30 days; infants suffering from any kind of 
disease influencing enteral feeding, including gastrointestinal malformations and 
necrotizing enterocolitis (NEC) or infants whose mother's milk was contraindicated 
(mothers with a history of drug abuse or HIV infection). 
All infants were randomized into a study group or a control group from a 1:1 
ratio random number table generated by computer. Allocation was hidden from nurses, 
doctors and parents. Only the principal investigator (PI) knew the allocation and 
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prepared the colostrum and normal saline in blinded syringes. The infants started their 
enteral feeding with nasogastric or orogastric tube. The attending physicians decided 
the feeding status based on the infants’ individual factors. In both groups infants were 
fed with preterm formula first followed by their mothers’ human milk. 
Sample size 
On the basis of results from pilot data, we supposed that a mean difference of the 
changes of sIgA at 7 days from baseline in saliva was 580 ng/ml between the two 
groups; the SD was 537 ng/ml in study group and 509 ng/ml in control group. With 
α=0.05 and β=0.1, we calculated 26 infants for each group. Assuming a 20% dropout 
rate, we estimated that 64 infants were needed. 
Intervention  
1. Collection of Colostrum 
Within 24 hours after delivery the infants were transferred to our NICU. The PI met 
with each father whose infant was enrolled in the study to educate the standardized 
protocol for milk removal utilizing an electric breast pump and hand expression of 
colostrum. Only fathers were contacted because mothers were at home or in the 
maternity hospital following the Chinese tradition of ‘zuo yuezi’ (‘sitting the month’). 
This tradition is a 30-day recovery of new mothers staying at home to protect their 
body against cold. Fathers were encouraged to help mothers pumping every 2-3 hours 
for a total of 8 times per 24-hour period; pour the colostrum separately into breast 
milk storage bags labeled with the infant’s information including the medical record 
number, the infant’s name, the date and time of colostrum pump and deliver the 
colostrum specimens to the NICU for immediate refrigeration. 
2. OAC Protocol 
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Once received the colostrum, the PI and another nurse checked the infant’s 
information against the label on the breast milk storage bags. In the control group we 
put the storage bags in -18
o
C freezer for cryopreservation until the infants start enteral 
feeding. In the study group we collected the storage bag with nearest pumping time, 
extracted 0.2ml of colostrum with 1ml sterile syringe and placed in room temperature 
for 5 minutes to bring the colostrum to room temperature for the OAC. Then put the 
bag in the refrigerator cold storage with temperature of 0-4
 o
C for the following 
intervention and the colostrum was stored for 24h. All the other storage bags were 
placed in -18
o
C freezer for cryopreservation until the infants start enteral feeding. 
The nurses followed an oropharyngeal administration protocol to administer the 
drops: Removed the needle and then put the syringe into the infant’s mouth along one 
side of the cheek gently. Adjust the syringe tip pointing the infant’s oropharyngeal. 
Administered 0.1 ml of the colostrum with constant speed over a period of at least 20 
seconds, then moved the syringe to the opposite side of the cheek and administered 
the remaining 0.1 mL of the colostrum in the same way. Control group infants also 
started with the oropharyngeal administration protocol using normal saline instead of 
colostrum. This protocol was carried out every 4 hours for 7 days.  
Monitoring and Recording 
The infants’ heart rate, respiration, pulse, blood pressure and oxygen saturation were 
monitored and recorded during the intervention. The intervention would be stopped 
and continue later when any of the following cases happened: the infant shows 
significant agitation, the infant’s basic vital signs changes (heart rate> 200 beats / min 




To measure the concentrations of sIgA and lactoferrin we collected saliva and urine 
specimens at three times: first time when parents agreed to participate in this study 
(T0); at 7 (T1) and 21 (T2) days of life. Sterile urine bags were used to collect urine 
specimens and weak suction to collect saliva in a sterile container. All specimens 
were centrifuged and frozen at -70
o
C until transported to the laboratory for 
biochemical analysis. The concentrations of sIgA and lactoferrin were measured using 
enzyme-linked immunosorbent assay kits. The sIgA kit (Jianglai Biological 
Technology, Shanghai, China), limit of detection was 1.5 ug/ml -48ug/ml. The 
minimum detectable dose is typically less than 0.1ug/ml. The lactoferrin kit ( Jianglai 
Biological Technology, Shanghai, China), limit of detection was 125ug/ml-4000ug/ml. 
The minimum detectable dose is typically less than 10ug/ml. Both of the kit 
coefficient of variations between kits were less than 10%, within kit coefficient of 
variations were less than 10%. 
Outcome measures 
To evaluate the local and systemic immune effect of OAC we measured the 
concentration of sIgA and lactoferrin in saliva and urine. The primary outcomes are 
the changes from baseline in sIgA and lactoferrin at the finish of OAC and two weeks 
later. We also collect the incidence of sepsis (clinical or proven) and NEC, time to 
reach full enteral feeding (140 ml/kg/day), time to start oral feeding (start bottle 
feeding by mouth >5ml/once) as secondary outcomes.  
According to the international sepsis definitions we defined clinical sepsis as 
clinical signs of infection with antibiotic treatment more than three days (16). Sepsis 
was confirmed if bacterial growth occurred in at least one blood culture and 
symptoms of clinical sepsis. We defined NEC grade ≥ II according to the modified 
Bell’ staging classification (17). Vital signs were assessed during the study period and 
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adverse events were recorded. Clinical data from each infant were collected until 
hospital discharge. 
Statistical Analysis 
Statistical analyses were performed using SPSS, version 21.0. Fisher’s exact tests and 
t-test were used to analyze clinical data. Changes from baseline in lactoferrin and 
sIgA between two groups were calculated by the t-test. 
Ethics 
The local institutional review board approved this study. The PI explained the purpose, 
process, voluntary participation and confidentiality of this study to the parents. A 
consent form was required to be signed before the study. The study was registered at 
the US National Institutes of Health (ClinicalTrials.gov) with number NCT02389478. 
 
RESULTS  
In total, 64 VLBW infants were included and randomly assigned to the control or 
study group. Four infants were excluded from the study group and five infants were 
excluded from the control group (Figure 1). In total, 55 infants (28 in the study group 
and 27 in the control group) completed the study protocol receiving totally 42 times 
of treatment during a period of 7 consecutive days. The median gestational age of the 
population was 30+2weeks (range: 25+2~33+4 weeks), and the median birth weight 
was 1245g (650~1490g). 
No significant differences were found in the baseline characteristics between both 
groups (Table 1). 
Figure 1: presents the level of sIgA and lactoferrin in saliva and urine (µg/ml). 
Data are presented as mean and standard deviation (SD). The saliva level of sIgA at 
T1 was 31.92+8.69 vs. 27.78+5.26 (p=0.04). Changes of sIgA and lactoferrin in 
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saliva and urine were measured at different time-points. The only statistically 
significant differences between the two groups were observed in lactoferrin in saliva 
between baseline and T1, 5.18+7.07 vs. -1.74+4.67 (p<0.001) and T2 5.31+9.74 vs. 
-1.17+10.38 (p=0.02) (Figure 2). 
No significant differences were observed in the secondary outcome measures 
between both groups at time of discharge (Table 2). However, the control group had a 




Since the first study in 2010 reported the safety and feasibility of OAC to extremely 
low birth weight infants, more researchers and clinicians have paid attention to OAC 
(18). Oropharyngeal administration of own mother’s colostrum is feasible and safe to 
VLBW infants. However, only a few studies have investigated the beneficial effects 
of OAC. One of these studies reported that the OAC may reduce the days reaching 
full enteral feeding (19). Another study reported the clinical advantages of OAC 
related to the immune system (20).  
In our double blind, randomized, placebo-controlled trial we were able to 
document significant differences on the changes of lactoferrin at 7 days from baseline 
in saliva. Also, difference in sIgA levels in saliva between both groups at 7 days of 
life was significant. However, the results did not confirm the differences on sIgA in 
the change from baseline to 7 and 21 days. Our results suggest that OAC may 
increase the concentration of local lactoferrin and might implicate a beneficial effect 
on the immunologic system of VLWB infants. 
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   We observed that the urinary concentration of lactoferrin and sIgA was not 
significantly increased in both of the groups, which was different from the study of 
Lee and colleagues (20). Three reasons might explain these differences. First, the 
inclusion criteria of our study were defined in terms of birth weight than gestation age. 
Therefore, the average gestation age at baseline in our study was 30 weeks and thus 
more mature than reported in the study of Lee and colleagues, 26
+5 
weeks. Previous 
studies have confirmed that immuno-protective factors in the colostrum are related to 
gestation age — more highly concentrated of mothers who deliver extremely preterm 
infants (6-8). Secondly, sIgA and lactoferrin are absorbed from breast milk via 
neonatal gut mucosa with subsequent excretion of their intact maternal forms in the 
urine (7,19,21,22). This exceptional mucosal absorption might be expected to occur 
only in preterm infants, particularly before “gut closure”. Thirdly, the half-lives of 
sIgA and lactoferrin are 3 to 6 days (21,23), shorter than the time of specimens’ 
collection. Therefore, future studies need to pay attention on extremely preterm 
infants and consider collecting specimens every day after OAC to observe trends of 
changes.   
In saliva concentration of lactoferrin we observed statistical differences on 
change from baseline, 7 days, and 21 days. Although we didn’t observe any other 
immunologic effect in our study, previous studies has shown that lactoferrin plays an 
important role in the establishment of immune system. It can decrease the incidence 
of late-onset sepsis and NEC grade ≥ II in preterm infants (24-26). It suggests that 
OAC may increase the concentration of lactoferrin in saliva and then enhance local 
mucosal immunity. In our study the average time to start the OAC was 69.45±34.34 
hours after the infants’ birth. Previous study have confirm the concentration of 
lactoferrin in colostrum from mothers delivered before 33 weeks of gestation 
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appeared significantly higher than in colostrum from mothers delivered full-term baby 
(10), and it decrease slowly and maintain rather constant values (9). Thus, OAC has 
effect on lactoferrin even if the start time is nearly three days later after birth. 
We observed differences in sIgA levels in saliva between both groups after 7 
days of OAC. No differences were found on changes from baseline, 7 and 21 days in 
urine and saliva. Because the changes play a more important role, we believe OAC 
did not have an impact on the concentration of sIgA in saliva in this study. This might 
be because the average time to start OAC was 69.45±34.34 hours after the infants’ 
births. This was a delay of more than one day compared to the study of Montgomery 
et al., 40±28 hours (22). Evidence confirmed that the levels of sIgA in colostrum were 
significantly more elevated on the first day after delivery when compared with other 
days (27). On the fourth day, the concentration of sIgA was almost a tenth of the first 
day (27). Thus, when we started the OAC the concentrations of sIgA were decreased, 
and the impact on immunologic effect may also have decreased. The delayed start of 
OAC was because of the delayed acquired of colostrum. Our study was conducted in 
a NICU in a stand-alone children’s hospital where mothers and infants were separated. 
We were only able to provide education about breast feeding to the infants’ father or 
other family members instead of to their mother directly. We also needed to rely on 
other family members to transport the colostrum to the hospital. The delayed first 
time to administer the colostrum resulted in a delayed start of the OAC intervention. 
Future studies need to consider the cooperation with maternity hospitals to ensure that 
mothers can obtain relevant knowledge after postpartum, start pumping earlier, 
shorten the time to obtain the initial colostrum, and shorten the time to start OAC.  
The difference of days in reaching full enteral feeding (140ml/kg.d
-1
) between 
two groups has no statistical significance. However, we observed an 8-days-delayed 
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to reach full enteral feeding in the control group. Previous studies pointed that the 
impact of human milk on prematurity-related morbidities has emerged as a 
dose-response relation (28,29), and infants with a delayed achievement of full 
feedings are at risk of NEC [30](30). It is interesting to note that although there were 
no differences about the incidence of NEC between the two groups, we notices that 
five of the 28 infants in the control group developed NEC while only one infant in the 
study group. Evidence suggests that oral lactoferrin prophylaxis can decreases the 
incidence of NEC stage II or greater in preterm infants without adverse effects (30). 
Colostrum contains high concentration of lactoferrin and other immunomodulatory 
nutrients which have a potential protection to prevent the incidence of NEC (31-34).  
Limitations 
Our study was conducted in a children’s hospital without a maternity ward and 
the NICU has limited rooms for parents to stay. Therefore, maternal separation causes 
delay in delivering the colostrum to the NICU. The sample size included in this study 
could not effectively test the difference in secondary outcomes between two groups. 
Therefore, future studies need to consider expanding the sample size based on other 
power variables. 
CONCLUSION 
Our results suggest that OAC can increase the concentration of lactoferrin in saliva 
but the effect on other immune-protective agents was not confirmed. We recommend 
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Table 1. Patient Demographics 
 
 Study group 
(n = 32) 
Control group  
(n = 32) 
Gestational age in weeks: mean, (SD) 29.86 (2.02) 30.46 (2.50) 
Birth weight in grams: mean, (SD) 1241 (275) 1248 (233) 
Gender: Male (n) 18 17 
Apgar score at 1 min: mean, (min- max) 7 (3~10) 8 (3~10) 
Apgar score at 5 min: mean, (min- max) 8 (4~10) 8 (1~10) 
Multiple gestation: Yes (n) 13 12 
Vaginal delivery: Yes (n) 8 9 
Receiving colostrum in hrs: mean, (SD) 67.3 (36.1) 69.4 (34.4) 
Start enteral feeding in days: mean, (SD) 2.0 (0.5) 2.3 (1.5) 





Table 2. Clinical outcomes between two groups at the time of discharge. 
 
 Study group 
(n = 27) 
Control group 
(n = 28) 
P-value 
NEC, stage≥2; (n) 1 5 0.10
a
 
Clinical sepsis; (n) 4 8 0.61
a
 
Proven sepsis; (n) 3 6 0.17
a
 
Days starting oral feeding, >5ml; 
mean (SD) 
15.38 (10.74) 16.29 (10.13) 0.75
b
 
Days reaching full enteral feeding; 
mean (SD) 




 Fisher’s exact test; 
b
 t-test; NEC= necrotizing enterocolitis 
 
